Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study
Open Access
- 14 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (2)
Abstract
Chemotherapy-induced cognitive impairment (CICI) is a well-recognized side effect of breast cancer treatment. However, prospective long-term evaluations of CICI using standardized neuropsychological tests are scarce. This prospective longitudinal cohort study investigated cognitive dysfunction and its impact on quality of life and everyday functioning in patients with breast cancer receiving first-line chemotherapy compared to patients with breast cancer without chemotherapy. Assessment occurred prior to chemotherapy, postchemotherapy (median 6 months), and 2-3 years later. We used standardized neuropsychological tests, questionnaires, and scales to assess patients’ quality of life and functioning. Additionally, serum analysis for neurodegenerative markers and autoantibodies was conducted. We included n = 53 patients. Overall cognitive function declined statistically significantly (P = .046) postchemotherapy compared to control patients, mostly driven by a reduced figural memory (P = .011). Patients who received chemotherapy showed a greater reduction in quality of life (increased fatigue symptoms, P = .023; reduced Karnofsky index, P < .001); however, without a statistically significant effect on cognitive decline. The neurodegenerative markers Neurofilament light chain (NfL) and phosphorylated Neurofilament heavy chain (pNfH) increased statistically significantly (P < .001) postchemotherapy and pNfH correlated with overall cognitive function. After 2-3 years, both cognitive performance and quality of life were comparable between chemotherapy-treated and control patients. Our findings suggest that chemotherapy statistically significantly contributes to overall cognitive dysfunction in patients with breast cancer, which disappears after 2-3 years, indicating a recovery in both objectively measurable cognitive function and subjective quality of life. Future research should examine larger sample sizes and explore screening indicators, particularly pNfH.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
- Center for Stroke Research Berlin (01 EO 0801)
- Else-Kröner-Fresenius Stiftung (2020_EKEA.80)
This publication has 23 references indexed in Scilit:
- Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysisScientific Reports, 2022
- Blood and neuroimaging biomarkers of cognitive sequelae in breast cancer patients throughout chemotherapy: A systematic reviewTranslational Oncology, 2021
- Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung CancerJAMA Oncology, 2021
- Chemotherapy-related cognitive impairment in patients with breast cancer based on MRS and DTI analysisBreast Cancer, 2020
- A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 miceTranslational Psychiatry, 2017
- A meta-analysis of cognitive impairment following adult cancer chemotherapy.Neuropsychology, 2014
- Prevalence ofN-Methyl-D-Aspartate Receptor Autoantibodies in the Peripheral BloodJAMA Psychiatry, 2014
- Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic reviewCancer Treatment Reviews, 2012
- Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI studyBreast Cancer Research and Treatment, 2010
- A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive functionCancer, 2005